GleamWall
中文EN

GMAB GENMAB A/S IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1434265

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY19.2%
TTM net income YoY-15.0%
TTM EPS YoY-12.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin93.6%
Operating margin28.6%
Net margin25.9%
FCF margin30.9%
EBITDA margin—

Returns

ROE17.5%
ROA10.0%
ROIC (approx.)12.9%
Asset turnover0.39x

Leverage & solvency

Liabilities / assets54.6%
Debt / equity0.90x
Current ratio2.02x
Interest coverage3.96x

Cash quality & payout

Operating cash flow / net income1.23x
Accruals ratio-2.3%
Payout ratio—
Capex / revenue1.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2025*2025-12-31FY2024*2024-12-31
Income statement
Revenue$3.72B$3.12B
Cost of revenue$238.00M$143.00M
Gross profit$3.48B$2.98B
R&D expense$1.61B$1.41B
SG&A expense$626.00M$549.00M
Operating income$1.06B$972.00M
Interest expense$269.00M$291.00M
Pretax income$1.20B$1.33B
Income tax$241.00M$193.00M
Net income$963.00M$1.13B
EPS (basic)15.5017.66
EPS (diluted)15.3717.53
Weighted avg. shares (diluted)62.69M64.66M
Balance sheet
Cash & equivalents$1.72B$1.38B
Receivables$1.11B$923.00M
Inventory$18.00M$9.00M
Current assets$2.88B$3.90B
PP&E, netmay include right-of-use assets (IFRS)$153.00M$137.00M
Goodwill$355.00M$355.00M
Intangibles$9.12B$1.73B
Total assets$12.87B$6.41B
Current liabilities$1.43B$744.00M
Short-term debt$273.00M$0
Long-term debt$5.00B$0
Total debt$5.27B$0
Total liabilities$7.03B$1.28B
Shareholders' equity$5.85B$5.14B
Net debt$3.56B-$1.38B
Shares outstanding64.24M66.19M
Cash flow statement
Operating cash flow$1.19B$1.13B
Capital expenditure$37.00M$27.00M
Free cash flow$1.15B$1.10B
Investing cash flow-$5.64B-$1.45B
Financing cash flow$4.79B-$566.00M
Stock-based compensation$128.00M$105.00M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.